Peer-influenced content. Sources you trust. No registration required. This is HCN.

First-Line Pembrolizumab Combo Improves PFS in Patients w. Extensive-Stage SCLC

The Journal of Clinical Oncology published the double-blind, phase 3 KEYNOTE-604 clinical trial study results, which sought to compare pembrolizumab plus etoposide and platinum (EP) with placebo plus EP in treatment-naïve patients with ES-SCLC.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form